



JC19 Rec'd PCT/PTO 22 MAY 2001 PCT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Tasuku HONJO et al.

Appln. No.: 09/674,330

Filed: October 30, 2000

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: A NOVEL POLYPEPTIDE, A cDNA ENCODING THE POLYPEPTIDE AND  
UTILIZATION THEREOF

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include any new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
3. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by

**STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

**Q61536**

fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,




---

Drew Hissong  
Registration No. 44,765

SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: May 22, 2001



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Tasuku HONJO et al.

Appln. No.: 09/674,330

Filed: October 30, 2000

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: A NOVEL POLYPEPTIDE, A cDNA ENCODING THE POLYPEPTIDE AND  
UTILIZATION THEREOF

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR  
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Response is in reference to the Notification to Comply, mailed April 20, 2001, issued in the above referenced patent application. As the Notification to Comply was mailed April 20, 2001, and set a two month period for response, this response is timely filed as it is being filed on or before June 20, 2001.

In the Notification to Comply, the Examiner states that the Sequence Listing on file in the present application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825 for the reasons set forth in the attached Raw Sequence Listing Error Report.

The Report states that the term "n" in SEQ ID NO: 2 is undefined, and that field <220> is mandatory when fields <221>, <222> or <223> are used. In response, Applicants have amended

**RESPONSE TO NOTIFICATION TO COMPLY**

**Q61536**

the Sequence Listing to comply with 37 C.F.R. § 1.823(b), correcting the errors noted by the Examiner.

In addition to the present Response to Notification to Comply, Applicants file herewith a paper copy and copy in computer readable form of the Sequencing Listing, a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825, and a copy of the Notification to Comply.

Applicants assert that the Response to Notification to Comply and the enclosures are being timely filed, and that the enclosures bring the present application in full compliance with the requirements of 37 C.F.R. §§1.821-1.825.

Accordingly, Applicants respectfully request that the Examiner acknowledge that the Sequence Listing in the present application meets the requirements of 37 C.F.R. §§1.821-1.825.

Respectfully submitted,



Drew Hissong  
Registration No. 44,765

SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: May 22, 2001